Home environmental exposures and progression of fibrosing interstitial lung disease
Domestic Environmental Exposure and Progression of Fibrosing Interstitial Lung Diseases: An Exploratory Case-Control Study
Ville de Paris · NCT07457502
This project will try to see if indoor and outdoor pollutants and other home risk factors are linked to fibrosis getting worse in adults with fibrosing interstitial lung disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ville de Paris (other gov) |
| Locations | 2 sites (Paris, Paris and 1 other locations) |
| Trial ID | NCT07457502 on ClinicalTrials.gov |
What this trial studies
This is a case-control observational project enrolling 60 adults with either progressive or non-progressive fibrosing ILD, matched by ILD subtype and antifibrotic treatment status. Researchers will perform detailed home environmental audits measuring nitrogen dioxide, volatile organic compounds, aldehydes, fine particles, mold, dust mite allergens, building defects, and lifestyle factors that affect exposure, and will link these data to ambient air quality at each participant's address. Occupational exposures will be recorded and included in the analysis to separate home from workplace risks. The goal is to describe domestic exposures comprehensively and test associations between those exposures and recent fibrosis progression.
Who should consider this trial
Good fit: Adults (≥18) with fibrosing ILDs such as IPF, NSIP, CHP, PPFE, fibrosing sarcoidosis, pneumoconioses, or unclassifiable ILD who have had either progressive or non-progressive fibrosis over the past 12 months and meet matching and treatment-stability criteria are eligible.
Not a fit: Patients whose disease is driven mainly by clearly identified non-domestic exposures, who cannot permit a home audit, or who had reductions in ILD treatment in the prior 12 months are unlikely to gain benefit from participation.
Why it matters
Potential benefit: If successful, the study could identify modifiable home or neighborhood exposures that patients and clinicians might target to help slow fibrotic progression.
How similar studies have performed: Prior studies have linked outdoor air pollution to worse ILD outcomes and suggested household exposures may matter, but comprehensive paired home-audit case-control studies of this kind remain relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged over 18 years * Patient affected by one of the following interstitial lung diseases (ILDs): Idiopathic Pulmonary Fibrosis (IPF), Nonspecific Interstitial Pneumonia (NSIP), Pneumoconioses, ILDs associated with autoimmune features, Pleuroparenchymal Fibroelastosis (PPFE), Chronic Hypersensitivity Pneumonitis (CHP) whose etiology is not primarily related to the domestic environment, Stage 4 fibrosing sarcoidosis, unclassifiable ILDs. * ILD patient with progressive fibrosis over the past 12 months (case group) * ILD patient with non-progressive fibrosis over the past 12 months (control group) * Patients without reduction in the treatment of interstitial lung disease in the 12 months prior to inclusion, patients without treatment can be included * Matching "1 progressive fibrosis" / "2 non-progressive fibrosis": * Same ILD diagnosis * Use of antifibrotic treatment for both paired patients or absence of antifibrotic treatment for both paired patients * Both patients should preferably be matched within 3 months to limit significant contrasts in lifestyle and housing use related to the season * Patient who has received information about the protocol and does not object to participating * Patient affiliated with or beneficiary of a social security scheme or universal health coverage Exclusion Criteria: * Patient who has already received advice from a CMEI (Environmental and Occupational Medicine Consultation Center) in the past 12 months * Patient who has recently moved into their home (less than 1 year) * Patient living less than 6 months per year in the home to be investigated * Patient followed in psychiatry for a severe condition * Patient who does not speak French and is not accompanied by a person who shares their home and speaks French to act as a translator * Patient refusing to consent to participate in the research * Patient not living in Île-de-France * Patient with non-chronic Hypersensitivity Pneumonitis related to the domestic environment * Patient with sarcoidosis (except stage 4 fibrosing sarcoidosis) * Adult patient under legal protection and unable to give consent
Where this trial is running
Paris, Paris and 1 other locations
- Hôpital Paris Saint Joseph — Paris, Paris, France (RECRUITING)
- Hôpital de Tenon — Paris, Paris, France (RECRUITING)
Study contacts
- Principal investigator: Jean-Marc NACCACHE, 1 — Groupe Hospitalier Paris Saint Josèphe
- Study coordinator: Valerie BEX, 1
- Email: valerie.bex@paris.fr
- Phone: +33144978771
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Assess PID Diagnosis Revision After CMEI Audit, Assess CMEI Recommendations', Impact on Respiratory Health, ILD Progression and Exposure to Indoor Environnemental Risk, ILD Progression and Exposure to Outdoor Polluants, Interstitial Lung Disease, Air polution, fibrosing